title: Platelet-derived growth factor receptor beta serum concentrations during first-line therapy in ovarian cancer.
abstract: OBJECTIVE
  Angiogenesis plays an important role in ovarian cancer. The interaction of platelet-derived growth factor receptor-beta (PDGFR-β) with vascular endothelial growth factor (VEGF) in the process of angiogenesis may represent an essential feature in the progression of the disease.
  
  
  METHODS
  Patients with epithelial ovarian cancer, who underwent primary surgery and platinum-based first-line chemotherapy, were included. A total of 133 serum samples from 39 patients were analyzed. Samples were prospectively collected at 4 time points: (1) before surgery, (2) after surgery and before chemotherapy, (3) during chemotherapy and (4) after chemotherapy. Serum PDGFR-β was quantified by ELISA. We analyzed the correlation of serum levels to chemotherapy response, progression-free and overall survival (PFS and OS) and the serum markers CA-125 and VEGF-165.
  
  
  RESULTS
  Serum concentration of PDGFR-β ranged between 4 and 72 ng/ml and increased significantly during first-line chemotherapy (p = 0.019). PDGFR-β serum concentrations showed an inverse correlation with CA-125 and VEGF-165 after chemotherapy (r = -0.495, p = 0.003 and r = -0.345, p = 0.04, respectively). Increased PDGFR-β serum levels after chemotherapy were significantly correlated with better PFS (p = 0.026) and OS (p = 0.013) in a univariate analysis.
  
  
  CONCLUSIONS
  PDGFR-β might be a useful biomarker in terms of prognosis and could be important as antiangiogenic agents become a component of standard treatment in ovarian cancer.
authors.affiliation: Department of Gynecology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany.
authors.forename: Sabrina
authors.initials: S
authors.lastname: Mathey
authors.forename: Monika Karla
authors.initials: MK
authors.lastname: Graeser
authors.forename: Christine
authors.initials: C
authors.lastname: Zu Eulenburg
authors.forename: Linn
authors.initials: L
authors.lastname: Woelber
authors.forename: Fabian
authors.initials: F
authors.lastname: Trillsch
authors.forename: Fritz
authors.initials: F
authors.lastname: Jaenicke
authors.forename: Volkmar
authors.initials: V
authors.lastname: Müller
authors.forename: Karin
authors.initials: K
authors.lastname: Milde-Langosch
authors.forename: Sven
authors.initials: S
authors.lastname: Mahner
mesh_terms: D000328:Adult; D000368:Aged; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D014408:Biomarkers, Tumor / Q000097:blood*; D018394:CA-125 Antigen / Q000097:blood; D016190:Carboplatin / Q000008:administration & dosage; D000077216:Carcinoma, Ovarian Epithelial; D018572:Disease-Free Survival; D005260:Female; D006801:Humans; D060828:Induction Chemotherapy; D053208:Kaplan-Meier Estimate; D008875:Middle Aged; D009375:Neoplasms, Glandular and Epithelial / Q000097:blood* / Q000188:drug therapy / Q000401:mortality; D010051:Ovarian Neoplasms / Q000097:blood* / Q000188:drug therapy / Q000401:mortality; D017239:Paclitaxel / Q000008:administration & dosage; D020797:Receptor, Platelet-Derived Growth Factor beta / Q000097:blood*; D016896:Treatment Outcome; D042461:Vascular Endothelial Growth Factor A / Q000097:blood
chemical_list: D014408:Biomarkers, Tumor; D018394:CA-125 Antigen; C467484:VEGFA protein, human; D042461:Vascular Endothelial Growth Factor A; D016190:Carboplatin; D020797:Receptor, Platelet-Derived Growth Factor beta; D017239:Paclitaxel